- Astellas Pharma has revised its full-year net income forecast to 14.00 billion yen.
- The previous forecast for net income was 50.00 billion yen.
- Analysts had estimated net income to be 73.81 billion yen.
- The company now expects operating income to be 11.00 billion yen, previously projected at 80.00 billion yen.
- Net sales expectations have been increased to 1.90 trillion yen, up from the prior forecast of 1.80 trillion yen.
- The market had estimated net sales to be slightly lower at 1.81 trillion yen.
- Among analysts, there are 9 buy recommendations, 7 hold recommendations, and 1 sell recommendation for Astellas Pharma‘s stock.
- These comparisons are made in relation to figures from the company’s original disclosures.
Astellas Pharma on Smartkarma
Analysts on Smartkarma, including Tina Banerjee, have been providing insightful coverage of Astellas Pharma. In a recent research report titled “Astellas Pharma (4503 JP): US Momentum Drives 1HFY25 Result; Guidance Revised Upward,” the focus is on the company’s impressive 22% revenue growth in the first half of FY25, largely attributed to strong sales of Xtandi. The report highlights Astellas’ optimistic outlook for the future, with Xtandi and Padcev identified as key drivers expected to contribute significantly to revenue, amounting to 57% in FY25. The company has raised its revenue guidance for the fiscal year by 9%, showcasing confidence in its growth trajectory despite margin pressures.
A look at Astellas Pharma Smart Scores
| Factor | Score | Magnitude |
|---|---|---|
| Value | 3 | |
| Dividend | 5 | |
| Growth | 2 | |
| Resilience | 2 | |
| Momentum | 2 | |
| OVERALL SMART SCORE | 2.8 |
Smart Score is a compound score for the Company indicating its overall outlook. It is derived by taking an equally weighted average of underlying Factor scores computed by Smartkarma
Based on the Smartkarma Smart Scores, Astellas Pharma shows a strong performance in terms of dividends, with a perfect score of 5. This indicates that the company is likely to provide stable and attractive dividends to its investors over the long term. However, when it comes to growth, resilience, and momentum, Astellas Pharma scores lower, with scores of 2 for each. This suggests that the company may face challenges in terms of its growth potential, ability to withstand external shocks, and momentum in the market.
Despite these mixed scores, Astellas Pharma Inc. remains a significant player in the pharmaceutical industry, focusing on various therapeutic fields such as Urology, Immunology, Oncology, Neuroscience, and Metabolic Diseases. With a global workforce of over 17,000 employees, the company’s presence spans across the US, Europe, and Asia. Investors should carefully consider the company’s strengths in dividends alongside its growth, resilience, and momentum factors to make informed decisions about its long-term outlook.
Disclaimer: This article by Smartkarma is general in nature and based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Note that our articles may not factor in the latest price-sensitive company announcements or qualitative material.
While all reasonable care has been taken in the preparation, Smartkarma makes no assurance about the accuracy of any generated data or content. All content is indicative only and should be independently checked for accuracy and confirmed before use. Smartkarma accepts no responsibility for any loss or damage caused as a result of any inaccuracy or error within the Lab online tools or generated data.
Have feedback on this article? Concerned about the content? Get in touch with us directly.
💡 Before it’s here, it’s on Smartkarma
Sign Up for Free
The Smartkarma Preview Pass is your entry to the Independent Investment Research Network
- ✓ Unlimited Research Summaries
- ✓ Personalised Alerts
- ✓ Custom Watchlists
- ✓ Company Analytics and News
- ✓ Events & Webinars
